An Overview Of Amicus Therapeutics: Everything You Ever Wanted To Know and More
When and How Was Amicus Therapeutics Founded?
Amicus Therapeutics is a biopharmaceutical company. The company first went public in 2007. It had planned to go public back in 2006, but the plans were withdrawn based on circumstances beyond their control. Prior to their public outing, several different venture capital companies helped to fund Amicus Therapeutics. Learn more about job offerings of Amicus Therapeutics at indeed.com.
Three of the firms that helped to fund Amicus Therapeutics
1) Radius Ventures
2) New Enterprise Associates
3) Canaan Partners
These three firms are still involved with Amicus Therapeutics, though others have a joint effort with the funding.
The History of Amicus Therapeutics and What It Does
The company’s focus is on rare diseases, sometimes orphaned. There are many diseases and disorders that are not talked about. This is where this company comes in. One of the primary disorders this company focuses on is Lysosomal Storage Disorder.
The Chaperone-Advanced Replacement Therapy is one another one of the key focuses for this disorder and many others. It is this platform that has won praise from many specific key-note speakers in the fight against this disorder. Visit Google Finance to know more about Amicus Therapeutics.
There are other diseases that Amicus Therapeutics concentrates on as well. Chief among them is Fabry Disease. The company has won many grants over the years, including The Michael J. Fox Foundation and the David Geffen School of Medicine.
Three Key People Who Help to Facilitate and Organize the Company Are:
1) John Crowley, who is the CEO
2) Brad Campbell, who is the COO
3) William Baird, who is the CFO